Q-omics provides the consensus-scored DNTT profile across patient tissues and cancer cell-line models. DNTT expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, DNTT is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, DNTT RNA expression shows 14,039 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, THCA, and THYM as cancer lineages where DNTT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DNTT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DNTT survival associations across molecular data types. DNTT RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DNTT RNA expression–survival associations across cancer types. High DNTT expression shows unfavorable associations in UVM, ACC, KIRC, COAD, MESO and OV. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for DNTT RNA expression.
This table summarizes DNTT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for DNTT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DNTT shows lower tumor expression in THCA and PRAD and higher tumor expression in KIRP, KICH, LIHC and LUAD. The THCA box plot shows higher DNTT RNA expression in normal versus tumor tissue (log2 FC = −0.841, t-test p < 0.001).
This table shows molecular features associated with DNTT in patient tissues and cancer cell lines. In patient samples, DNTT shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, DNTT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
